Dear IL-17 researchers,
IL-17 is now acknowledged as a key mediator of various chronic inflammatory diseases. Based on a wealth of data from clinical and basic research, 5 different therapies that target the IL-17/Th17 axis are already licensed, and even more are currently in development.
To obtain a deeper understanding of diseasedriving molecular networks and to identify novel therapeutic approaches, the intense collaboration of basic researchers and expert clinicians is essential.
Therefore, we look forward to welcoming you at the 3rd IL-17 Summit to share your experience, ideas and latest findings on IL-17 at this outstanding interdisciplinary meeting in Munich. Extending the scope of our congress at this year’s meeting, we are also going to cover the fascinating field of IL-1 -mediated autoinflammation and feature lectures on exciting new technologies that are going to revolutionize future research.
Burkhard Becher, Dirk Föll, Ulrich Mrowietz, Ulf Müller-Ladner, Ulf Panzer, Ari Waisman
Scientific Steering Committee